<DOC>
	<DOCNO>NCT01775631</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability maximum tolerate dose Urelumab combination Rituximab patient B-cell Non-Hodgkins Lymphoma</brief_summary>
	<brief_title>Combination Study Urelumab Rituximab Patients With B-cell Non-Hodgkins Lymphoma</brief_title>
	<detailed_description>Intervention model : Dose Escalation ( part 1 ) study= Sequential Design ; Dose Expansion ( part 2 ) study= Parallel Design</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Clinical diagnosis relapsed/refractory Bcell Malignancies ( BNonHodgkins Lymphoma ( NHL ) ) per International Workshop Group ( IWG ) Progressed refractory least 1 prior line standard therapy Subjects Expansion cohort restrict relapsed/refractory diffuse large Bcell lymphoma ( DLBCL ) Follicular Lymphoma ( FL ) subject either relapsed refractory prior rituximab ritxumabcontaining chemotherapy regimen Follicular Lymphoma ( FL ) must least 1 lesion biopsied screen treatment Eastern Cooperative Oncology Group ( ECOG ) 0 1 Active progress brain metastasis Other concomitant malignancy ( exception per protocol ) Active history autoimmune disease Positive test human immunodeficiency virus ( HIV ) 1 &amp; 2 know Acquired immune deficiency syndrome ( AIDS ) History hepatitis ( A , B C ) History grade 34 drugrelated hepatitis Known current drug alcohol abuse Active tuberculosis ( TB ) Prior therapy antibody/drug target T cell coregulatory protein , include limited , antiCD137 , Anti Cytotoxic T lymphocyteassociated antigen 4 ( antiCTLA4 ) AntiGlucocorticoidinduced tumor necrosis factor receptor ( antiGITR ) . However , AntiProgrammed Death1 ( antiPD1 ) , AntiProgrammed DeathLigand1 ( antiPDL1 ) permissible prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>